Cancer Genetics, Inc. Announces Appointment of Venkatadri Bobba to Cancer Genetics India's Board of Directors

Cancer Genetics, Inc. Announces Appointment of Venkatadri Bobba to Cancer Genetics India's Board of Directors

(Nasdaq:CGIX) ("CGI" or "the Company"), an emerging leader in DNA-based cancer diagnostics, announced today the addition of Venkatadri Bobba to Cancer Genetics India's Board of Directors.

"Mr Bobba has a tremendous track record of leadership in the life sciences. His experiences and insights will bring significant value to CG India's board of directors," said Panna Sharma, CEO and President of Cancer Genetics, Inc.

Bobba brings with him more than 36 years of corporate leadership experience in the pharmaceutical and life sciences industries.  Bobba, who is currently a General Partner with Ventureast, has held executive leadership positions at a number of life sciences companies in the US, EU, and Asia.  Prior to joining Ventureast, Bobba served as Senior Vice President of Operations at Aradigm Corporation and from 2001-2003 was Executive Vice President at Diosynth, a division of Akzo Nobel.  From 1995 to 2000, Bobba served as President and CEO at Molecular Biosystems, an NYSE listed company. Previous to that, Bobba was Executive Vice President of Centocor Inc (now Jansen Biotech, a division of Johnson & Johnson) and held several executive positions, including President, at Warner-Lambert, Indonesia. He also previously served as V.P. of Manufacturing at Parke-Davis, USA (now part of Pfizer).

"It is an exciting time to be part of such a high-growth market like India. I look forward to the growth and much needed innovation that CG India will bring to Indian cancer patients and hospitals at an affordable price," said Bobba. "CG India has established itself as a leader in the oncology diagnostics market with a firm commitment to innovation. I look forward to helping the company offer novel cancer diagnostic tests to all patients who need them to improve their clinical outcomes."

Bobba is an active board member of three US-based companies, including Diabetomics Inc., Melior Pharma, and Sparsha Inc. Bobba also sits on the board of several Indian-based companies, including Portea, Richcore, and Sparsha Pharma, an Indian subsidiary of Napo Pharmaceuticals. Additionally, he serves on the advisory board for the SOHO Group, the largest pharmaceutical company in Indonesia, and for Cumberland Pharmaceuticals, Inc., USA, a Nasdaq listed company.

A pharmacist by training, Bobba graduated with gold medal honors from Andhra University and holds an MBA from Farleigh Dickinson University, New Jersey.